drugset / Trial / NCT01666613

A Study in Healthy Subjects to Investigate Pharmacokinetics of AZD8683 When Administered in Different Ways

NCT01666613

Phase 1 Withdrawn AstraZeneca
RandomizedCrossoverOpen-labelBasic science

Summary

The purpose of this study is to look at drug levels of AZD8683 in blood when the drug is administered in different ways - orally, intravenously or inhaled (with two different devices), to healthy subjects

Timeline

Start
2012-11
Primary completion
2013-03
Completion
2013-03

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD8683 Unknown 100 ug Intravenous
Subject AZD8683 Unknown 540 ug Intravenous
Subject AZD8683 Unknown 600 ug Intravenous
Subject AZD8683 Unknown 950 ug Intravenous

Indications

No indication recorded.